ClinicalTrials.Veeva

Menu
A

Alina Clinical Trials | Dallas, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
UPB-101
Verekitug
S-217622
sodium
S-892216
PF-07275315
AMG 451
Lebrikizumab
Rimegepant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 14 total trials

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT st...

Enrolling
Severe Asthma
Drug: Verekitug
Drug: Placebo

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Active, not recruiting
Asthma
Drug: Placebo
Drug: Rocatinlimab

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Biological: Matching placebo

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal pol...

Enrolling
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Drug: Standard therapy for INCS
Drug: LY3650150

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Active, not recruiting
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of...

Enrolling
Asthma
Other: Placebo
Drug: PF-07275315

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and ado...

Enrolling
Migraine
Drug: Placebo
Drug: Rimegepant

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Amgen logo
U
Pfizer logo
Shionogi logo
A
Celldex Therapeutics logo
Lilly logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems